BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22018464)

  • 1. Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen.
    Liu T; Nedrow-Byers JR; Hopkins MR; Berkman CE
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7013-6. PubMed ID: 22018464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow cytometric detection of prostate tumor cells using chemoaffinity labels.
    Wu LY; Liu T; Grimm AL; Davis WC; Berkman CE
    Prostate; 2011 Jan; 71(1):52-61. PubMed ID: 20632319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.
    Liu T; Nedrow-Byers JR; Hopkins MR; Wu LY; Lee J; Reilly PT; Berkman CE
    Bioorg Med Chem Lett; 2012 Jun; 22(12):3931-4. PubMed ID: 22607680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A targeted low molecular weight near-infrared fluorescent probe for prostate cancer.
    Liu T; Wu LY; Hopkins MR; Choi JK; Berkman CE
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7124-6. PubMed ID: 20947349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.
    Nedrow-Byers JR; Moore AL; Ganguly T; Hopkins MR; Fulton MD; Benny PD; Berkman CE
    Prostate; 2013 Mar; 73(4):355-62. PubMed ID: 22911263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen.
    Liu T; Wu LY; Kazak M; Berkman CE
    Prostate; 2008 Jun; 68(9):955-64. PubMed ID: 18361407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of prostate cancer: optimizing affinity to prostate specific membrane antigen by spacer modifications in a tumor spheroid model.
    Krishnan MA; Pandit A; Sharma R; Chelvam V
    J Biomol Struct Dyn; 2022; 40(20):9909-9930. PubMed ID: 34180367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen.
    Liu T; Wu LY; Choi JK; Berkman CE
    Prostate; 2009 May; 69(6):585-94. PubMed ID: 19142895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway.
    Liu T; Wu LY; Choi JK; Berkman CE
    Int J Oncol; 2010 Apr; 36(4):777-84. PubMed ID: 20198319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen.
    Meher N; Seo K; Wang S; Bidkar AP; Fogarty M; Dhrona S; Huang X; Tang R; Blaha C; Evans MJ; Raleigh DR; Jun YW; VanBrocklin HF; Desai TA; Wilson DM; Ozawa T; Flavell RR
    ACS Appl Mater Interfaces; 2021 Nov; 13(46):54739-54752. PubMed ID: 34752058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent.
    Nedrow-Byers JR; Jabbes M; Jewett C; Ganguly T; He H; Liu T; Benny P; Bryan JN; Berkman CE
    Prostate; 2012 Jun; 72(8):904-12. PubMed ID: 22670265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors.
    Benešová M; Bauder-Wüst U; Schäfer M; Klika KD; Mier W; Haberkorn U; Kopka K; Eder M
    J Med Chem; 2016 Mar; 59(5):1761-75. PubMed ID: 26878194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of a novel near-infrared fluorescent probe based on succinimidyl-Cys-C(O)-Glu that targets prostate-specific membrane antigen for optical imaging.
    Matsuoka D; Watanabe H; Shimizu Y; Kimura H; Ono M; Saji H
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4876-4880. PubMed ID: 28964633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Biological Evaluation of PSMA Ligands with Aromatic Residues and Fluorescent Conjugates Based on Them.
    Machulkin AE; Shafikov RR; Uspenskaya AA; Petrov SA; Ber AP; Skvortsov DA; Nimenko EA; Zyk NU; Smirnova GB; Pokrovsky VS; Abakumov MA; Saltykova IV; Akhmirov RT; Garanina AS; Polshakov VI; Saveliev OY; Ivanenkov YA; Aladinskaya AV; Finko AV; Yamansarov EU; Krasnovskaya OO; Erofeev AS; Gorelkin PV; Dontsova OA; Beloglazkina EK; Zyk NV; Khazanova ES; Majouga AG
    J Med Chem; 2021 Apr; 64(8):4532-4552. PubMed ID: 33822606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells.
    Wu LY; Johnson JM; Simmons JK; Mendes DE; Geruntho JJ; Liu T; Dirksen WP; Rosol TJ; Davis WC; Berkman CE
    Prostate; 2014 May; 74(5):451-7. PubMed ID: 24449207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
    Nedrow JR; Latoche JD; Day KE; Modi J; Ganguly T; Zeng D; Kurland BF; Berkman CE; Anderson CJ
    Mol Imaging Biol; 2016 Jun; 18(3):402-10. PubMed ID: 26552656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
    J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Evaluation of Multifunctional Fluorescent Inhibitors with Synergistic Interaction of Prostate-Specific Membrane Antigen and Hypoxia for Prostate Cancer.
    Kwon YD; Oh JM; La MT; Chung HJ; Lee SJ; Chun S; Lee SH; Jeong BH; Kim HK
    Bioconjug Chem; 2019 Jan; 30(1):90-100. PubMed ID: 30485073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
    Dhar S; Gu FX; Langer R; Farokhzad OC; Lippard SJ
    Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17356-61. PubMed ID: 18978032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
    Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F
    Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.